Navigation Links
Researchers undertake radical new cancer survivorship study
Date:5/17/2012

Researchers from the Macmillan Survivorship Research Group (MSRG), at the University of Southampton, have developed the first study of its kind looking at the experiences and needs of people after primary treatment of colorectal cancer.

It is estimated that around two million people are living with, or beyond, cancer in the UK, with this figure rising by 3% each year. On average over 6,000 patients are diagnosed with cancer each year in Hampshire alone.

Whilst increasing cancer survival rates are to be celebrated, the experiences and needs of those who have completed their treatment have been relatively neglected until now.

The University of Southampton, which celebrates its 60th anniversary this year, has a long standing history of cancer research. It has developed the ColoREctal Wellbeing (CREW) study to look at a number of factors influencing recovery which takes into account the disease itself, the level of treatment patients receive, the support available to them and the range of coping skills they have.

Factors influencing recovery studied within the research include the time it takes a patient to return to feeling 'well', the length of time symptoms of treatment last and the range of things people can do to help return to 'normal' more quickly.

Results from this rigorous theory-informed study will, for the first time, inform health care providers and professionals across the country about what helps or hinders rapid and effective recovery and who has the confidence and ability to manage their own problems. It will also help identify areas for the development of interventions to aid the recovery process of those who may be at risk of experiencing problems.

More than 1,000 patients have been recruited to the study, one of whom is Susan Restorick-Banks from Totton in Hampshire.

Susan was diagnosed with a tumour in her colon in early 2011. She has endured Radiotherapy, surgery to remove the
'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-238-059-5457
University of Southampton
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Researchers make promising discovery in pursuit of effective lymphoma treatments
2. Breast cancer effectively treated with chemical found in celery, parsley by MU researchers
3. New biomarker test predicts arthritis at much earlier stage, MU researchers say
4. Researchers Test Laxative-Free Colon Scan
5. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
6. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
7. Researchers see BPA effects in monkey mammary glands
8. Geisel researchers sift through junk to find colorectal cancer clues
9. Email vacations decrease stress, increase concentration, researchers say
10. Researchers Rejuvenate Blood-Forming Stem Cells in Mice
11. CNIO researchers describe new functions of cohesin relevant for human disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and ... the opening of its new office to be located ... Business Parkway, Suite D, Greer, SC 29651. This new ... a more convenient location in the Greenville area. , ... the physicians, hospitals and patients we serve, to ensure ...
(Date:9/2/2014)... “Harmonicas have been formally used in ... help people with COPD or asthma. At this ... says Dana Keller, PhD, co-inventor of the Pulmonica. ... much the same – improved health with the ... , The three approaches to harmonicas in healthcare ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
(Date:9/1/2014)... BambooIndustry.com is one of the most ... famous for its high quality and elegant floors, plywoods, ... its new range of solid bamboo floors ... company has confidence in the new collection. BambooIndustry.com is ... of elegant bamboo items and great customer services. Also, ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth ... search for a new, larger headquarters. The newly ... the space of our office to 10,000 square feet. ... from glass topped cubicles with doors, to beautiful large conference ... warehouse," says Michael S. Rogers, CEO of Securityhunter. “Our ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2Health News:BambooIndustry.com: Solid Bamboo Floors Provided At Discounted Rates 2Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2
... RICHMOND, Va., Oct. 28 A leading authority on the ... a looming "caregiver crunch" impacting the ability of Americans to ... their loved ones. , On November 12, Dr. Dychtwald will ... coming "caregiver crunch" and the importance of long term care ...
... BLOOMINGTON, Minn., Oct. 28 The Child Neurology Foundation ... Spasms Awareness Week (October 11-17) that will go towards ... of epilepsy. , "Due to its rare nature, ... as it should be," said Lawrence Brown, M.D., Associate ...
... Biomedical Research Centre (BRC) for Mental Health at South ... of Psychiatry (IoP) , King,s College London (KCL) has ... support the development of the BRC,s Case Register Interactive ... research tool developed by the BRC,s cross-cutting Analytical Methodologies ...
... ... Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies ... entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as ... ...
... Health & Hospital System is responding to the ... expanding its language access program to include approximately ... other locations throughout Parkland Memorial Hospital. The unique, ... leading interpretation and translation provider, are used to ...
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today ... Centocor Ortho Biotech Inc. for development and commercialization of ... many solid tumors. , Under the terms ... worldwide license for the development, manufacture and sale of ...
Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 3Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 2Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 3Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 2Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2
(Date:9/1/2014)... , Sept. 1, 2014 ... report is available in its catalogue: ... 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... a new class of therapeutic agents, gaining increasing ... Generally addressed as the marriage of an antibody ...
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Implementing a Strategic Thought Leader Management & Engagement System 2
... Dec. 21, 2010 Bellicum Pharmaceuticals, Inc. today announced ... will be used to prepare for Phase II trials ... resistant prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy ... cell therapy (HSCT) setting. The new funding ...
... Dec. 21, 2010 The American Heart Journal ... Amorcyte, Inc.,s lead product candidate, AMR-001 for the treatment ...  Data demonstrated a significant relationship between cell dose and ... to prospectively define a dose of a purified and ...
Cached Medicine Technology:Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: